ILMN Earnings Prediction
The chart below shows how ILMN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ILMN sees a +0.77% change in stock price 10 days leading up to the earnings, and a -7.00% change 10 days following the report. On the earnings day itself, the stock moves by -0.35%. This data can give you a slight idea of what to expect for the next quarter's release.
ILMN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.10B
-1.60%
2.22%
Gross Margin
65.94%
9.77%
-4.41%
Operating Margin
19.02%
334.53%
-20.68%
Net Margin
16.94%
208.59%
-74.05%
EPS
1.18
206.31%
-73.24%
No Data Available
ILMN Earnings Analysis
Illumina Inc Corporation (ILMN.O) Earnings Conference Call
Positive
Q4 Revenue Performance: In Q4, Illumina achieved revenue of $1.1 billion, exceeding expectations and reflecting approximately 1% growth year-over-year, primarily driven by consumables.
Sequencing Consumables Revenue Growth: Sequencing consumables revenue reached $698 million, growing approximately 2% year-over-year, supported by the transition to the NovaSeq X series.
Sequencing Output Growth: Total sequencing GB output on connected high and mid throughput instruments grew over 30% year-over-year, indicating robust demand from both clinical and research customers.
Gross Margin Improvement: Non-GAAP gross margins improved to 67.4% in Q4, a 270 basis point increase year-over-year, driven by operational excellence initiatives and growth in consumables.
Strong Cash Generation: Illumina generated $364 million in cash flow from operations in Q4, with free cash flow of $322 million, demonstrating strong cash generation capabilities.
Negative
Sequencing Instruments Revenue Decline: Sequencing instruments revenue declined 3% year over year in Q4, primarily due to a decrease in mid throughput shipments caused by capital purchase and cash flow constraints affecting customer purchasing behavior.
Revenue Decline Analysis: Sequencing service and other revenue decreased by 1% year over year, mainly due to the timing of certain strategic partnership revenues from the previous year.
Revenue Outlook Decline: For Q1 2025, revenue is expected to be flat to down 1% year over year on a constant currency basis, driven predominantly by a decline in sequencing instruments and timing of certain strategic partnership revenues.
Cautious Revenue Growth Outlook: The guidance for 2025 anticipates low single-digit revenue growth, which reflects a cautious outlook amid ongoing macroeconomic and political uncertainties, particularly regarding the situation in China.
Regulatory Risk Assessment: The company is currently assessing the impact of recent regulatory announcements from China, which could pose a significant risk to the approximately 7% of total revenue derived from that market.
ILMN FAQs
How does ILMN typically perform around its earnings report dates?
Is Illumina Inc (ILMN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ILMN Earning Call Sentiment
Earnings call transcript: Illumina Q4 2024 beats EPS, stock falls
ILMN.O
-5.4%Positive
The earnings call presents a mixed picture. While there are positive aspects such as operational excellence, increased margins, and strategic collaborations, there are also challenges like flat revenue guidance, China-related uncertainties, and declining instrument sales. The Q&A session did not significantly alleviate concerns, especially regarding China. The company's cautious guidance and lack of clarity on certain issues contribute to a neutral sentiment. The stock price is likely to remain stable in the short term, with no major catalysts for a significant move in either direction.
